NCT03066752 is a clinical trial in Pediatric Multiple Sclerosis, sponsored by The Hospital for Sick Children.

Who is sponsoring NCT03066752?

NCT03066752 is sponsored by The Hospital for Sick Children.

What condition does NCT03066752 study?

NCT03066752 studies Pediatric Multiple Sclerosis.

Is NCT03066752 still recruiting?

NCT03066752 is currently completed. Last updated 7 January 2020.

Last reviewed 2020-01-07 · How we verify

NCT03066752

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes

Completed Last updated 7 January 2020

What this trial tests

trial in Pediatric Multiple Sclerosis in 20 participants. Completed in 24 November 2017.

Timeline

27 March 2017

Primary endpoint
24 November 2017

24 November 2017

Quick facts

Lead sponsor	The Hospital for Sick Children
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	27 March 2017
Primary completion	24 November 2017
Estimated completion	24 November 2017
Sites	1 location across Canada

Conditions studied

Pediatric Multiple Sclerosis — all drugs for Pediatric Multiple Sclerosis →

Sponsor

The Hospital for Sick Children

Who can join

Adults 6 to 18, any sex, with Pediatric Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Up to 65% of patients with multiple sclerosis (MS) experience cognitive dysfunction. Diminution of mental capacity has a pervasive and profound impact on their quality of life. Subtle changes in white matter predict cognitive changes in these patients but how this disrupts brain function remains unclear. Development of effective therapeutics to restore normal cognition hinges on elucidating these functional changes. The investigators seek to uncover the patho-physiological basis for cognitive decline in MS. The investigators hypothesize that cognitive decline originates from disrupted gamma oscillations and that gamma oscillations are disrupted by molecular changes triggered by demyelination.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cognitive Assessment and Rehabilitation for Pediatric-Onset Multiple Sclerosis: A Scoping Review.
Lin WS, Lin SJ, Hsu TR. · · 2020 · cited 3× · PMID 33076220 · DOI 10.3390/children7100183

Verify or expand the search:

Other The Hospital for Sick Children trials

Trials by the same sponsor.

NCT07454681 — MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure . · not yet recruiting
NCT07452575 — 3D Ultrasound in Hemophilic Ankles · NA · not yet recruiting
NCT07508826 — AI-assisted Endotracheal Intubation · NA · not yet recruiting
NCT07345819 — Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis · NA · not yet recruiting
NCT07497178 — MRgFUS for Childhood Epilepsy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03066752 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Hospital for Sick Children
Last refreshed: 7 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03066752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing